6,7-dimethoxy-4H-1-benzopyran | 162051-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6,7-dimethoxy-4H-1-benzopyran
• 英文别名: 6,7-dimethoxy-4H-chromene
• CAS: 162051-25-4
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: WITPYIVBOXNALK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4,5-二甲氧基-2-(2-丙烯基)苯酚 在 copper diacetate 、 [(N,N-(MeSO₂)2-imidazolidin-2-yl)RuCl₂(PCy₃)=CHPh] 、 氧气 作用下， 以 甲苯 、 乙腈 为溶剂， 生成 6,7-dimethoxy-4H-1-benzopyran
  参考文献：
  名称：

  合成苯并稠合双环化合物的开环易位

  摘要：

  闭环复分解（RCM）用于合成五个4 H-色烯，萘酚和茚满醇。这些是应用于此类苯并稠合双环化合物合成的RCM的第一个实例。

  DOI：

  10.1016/s0040-4039(02)02522-4

文献信息

• Intramolecular Hydroarylation of Alkynes Catalyzed by Platinum or Gold: Mechanism andendo Selectivity
  作者：Cristina Nevado、Antonio M. Echavarren

  DOI：10.1002/chem.200401069

  日期：2005.1

  The cyclization of differently substituted aryl alkynes with PtII or AuI catalysts proceeds by endo-dig pathways. When AgI was used to generate reactive cationic AuI catalysts, 2H-chromenes dimerize to form cyclobutane derivatives by a AgI-catalyzed process. A DFT study on the cyclization mechanism shows a kinetic and thermodynamic preference for 6-endo-dig versus 5-exo-dig cyclizations in PtII-catalyzed

  PtII或AuI催化剂对不同取代的芳基炔烃的环化作用是通过内挖途径进行的。当使用AgI生成反应性阳离子AuI催化剂时，2H-色烯通过AgI催化过程二聚形成环丁烷衍生物。DFT对环化机理的研究表明，在PtII催化的过程中，动力学上和热力学上偏爱6-内切与5-外切。计算表明，尽管Friedel-Crafts和通过金属环丙基碳烯的环丙烷化过程显示出非常相似的活化能，但是铂环丙基碳烯是能量最低的固定点。
• Ring-closing metathesis for the synthesis of 2H- and 4H-chromenes
  作者：Willem A.L. van Otterlo、E. Lindani Ngidi、Samuel Kuzvidza、Garreth L. Morgans、Simon S. Moleele、Charles B. de Koning

  DOI：10.1016/j.tet.2005.08.020

  日期：2005.10

  Six 4H-chromenes were synthesized from substituted phenols using vinylstannylation and ring-closing metathesis (RCM) as key steps. In addition, a different approach involving amongst other steps, an aryl allyl isomerization and RCM afforded a set of seven 2H-chromenes from phenolic precursors. (c) 2005 Elsevier Ltd. All rights reserved.
• [EN] CHROMENE ANALOGS AND USE THEREOF IN THE TREATMENT OF CANCER<br/>[FR] ANALOGUES DE CHROMÈNE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：OSMAN NİDAİ ÖZEŞ

  公开号：WO2015160321A1

  公开（公告）日：2015-10-22

  The present invention is about 8 different molecules, created from Chromene-2-one, their derivatives and pharmaceutical compositions containing these compounds. In generated 8 different molecule Rl and R2 positions were chosen as site of modifications, and these sites will be methyl (-CH3), ethyl (- C2H5), hydroxy! (-OH) and their combinations with one another. The compounds mentioned in this application have a potential to inhibit growth of various cancer cells, activate caspases and induce ceil death and prevent formation of new blood vessels by inhibiting synthesis of vascular endothelial cell growth factor (VEGF). Therefore, compounds mentioned in this application can be used to treat pancreas cancer, prostate cancer, skin cancer, ovarian cancer, bladder cancer, liver cancer, breast cancer, small-and non-smal-celi lung cancer, brain cancer, neuroblastoma, glioblastoma, cervical cancer, endometrial cancer, head and neck cancer, bone cancer, kidney cancer, thyroid cancer, osefagus cancer, lymphoma, sarcomas, cancers of general Gl track, stomach cancer, duodenum cancer, small intestine cancer, colon cancer, anal cancer, and types of leukemia.